As an industry pioneer, BioTel Care developed the first FDA-cleared, cellular-enabled glucometer which supports real-time transmission and consolidation of patient data in an FDA-cleared cloud.  Building on the success of this technology, BioTel Care is launching its next-generation blood glucose monitor, which includes an innovative touch-screen user interface, enabling patients to easily test blood glucose levels while capturing additional personal health data.  The monitor’s remote capabilities allow patients to quickly communicate a wide range of relevant health information to their care providers.  Clinicians can access and track their patients’ data through the BioTel Care cloud and can provide immediate feedback, as needed, directly to their patients via the new monitor’s messaging feature.  Patients can also track their own data with informative graphical summaries available on the monitor.  Both clinicians and patients will benefit from the system’s ability to be paired with other connected health devices, providing the option to consolidate various types of health information into a single, cloud-based repository.

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., noted: “This next generation blood glucose monitor is a great addition to our product portfolio and continues our commitment to innovate connected health solutions suited for today’s rapidly evolving healthcare market.  The design emphasizes usability, encouraging greater compliance and improved patient engagement.  The BioTel Care monitor also features the ability to consolidate data from other connected health devices, uniquely positioning us to move beyond diabetes and into the management of other chronic conditions.”

About BioTelemetry
BioTelemetry, Inc. is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  The BioTel Care division, formerly known as Telcare, was acquired by BioTelemetry in December 2016.  Telcare, a leading digital-health company, pioneered development of the first FDA-cleared, cellular-enabled glucometer and cloud-based diabetes data repository.  The Company’s focus is on providing a comprehensive suite of offerings to support diabetes management, combining a connected glucometer, cloud-based analytics and care management tools that enhance care for people living with diabetes.  More information can be found at www.gobio.com.

Contact:
BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
InvestorRelations@biotelinc.com